Recently, CRISPR-mediated KMT2A rearrangement (KMT2Ar) in human umbilical cord blood (UCB) hematopoietic stem and progenitor cells (HSPCs) was used to model aspects of leukemia biology (2–4). This evidence concerns the gene KMT2A and leukemia.